Th e consumption of excess calories as carbohydrates (CHO)-rich, protein-poor snacks characterizes the overeating of obese CHO cravers, premenstrual women, patients with Seasonal Affective Disorder, and former smokers. This specific appetite for CHOs may involve m-ain serotonin, as the synthesis and release of this neurotransmitter can increase following consumption of CHG-rich foods. To examine whether weight loss produced by serotoninergic drugs involves a selective reduction in CHO intake, obese females who consumed at least 30% of their daily calories from CRO-rich snacks were treated with dexfenfluramine ({DFJ 15 mg b.i. Seven FL subjects, 2 PL subjects, and 1 DF subject withdrew from the study due to side effects; other withdrawals were due to intercurrent illness or personal problems. Prior to treatment, subjects consumed over 40% of their daily CRO intake from snacks. Both of the drugs selectively decreased CRO snack intake (p < 0.05); DF, but not FL, also decreased meal CRO intake (p < .025). These results suggest that weight loss following treatment with serotoninergic drugs may relate to a selective decrease in CRO appetite. [Neuropsychopharmacology 9:201-210, 1993] brain neurotransrnission by blocking brain serotonin reuptake; OF through its metabolite, nordexfenflura mine, also releases serotonin into synapses.
0.22 kg ± 0.06 (mean ± SEM); for 21 of 28 DF completers, 0.56 ± 0.08 kg; and for 18 of 30 FL completers, 0.58 ± 0.09 kg (PL < DF = FL; p = .039). Seven FL subjects, 2 PL subjects, and 1 DF subject withdrew from the study due to side effects; other withdrawals were due to intercurrent illness or personal problems. Prior to treatment, subjects consumed over 40% of their daily CRO intake from snacks. Both of the drugs selectively decreased CRO snack intake (p < 0.05); DF, but not FL, also decreased meal CRO intake (p < .025). These results suggest that weight loss following treatment with serotoninergic drugs may relate to a selective decrease in CRO appetite. [Neuropsychopharmacology 9:201-210, 1993] brain neurotransrnission by blocking brain serotonin reuptake; OF through its metabolite, nordexfenflura mine, also releases serotonin into synapses.
It has been suggested that the weight loss produced by these drugs may be related to their effect in spe ciftcally decreasing the excessive intake of CHO-rich foods (Wurtman et al. 1985; Ferguson and Feighner 1987) . Because such foods are usually rich in fat, reduc ing CHO intake can account for a substantial reduction in total calorie intake (Wurtman et al. 1985; Ferguson and Feighner 1987) . Brain serotonin appears to influ ence CHO consumption; evidence from studies in which animals or human volunteers were treated with dietary or pharmacologic interventions that increase serotonin-mediated neurotransrnission indicates selec tive decreases in consumption of CHO-rich foods (Blun dell 1992; Leibowitz and Shor-Posner 1987; Luo and Li 1991; Wurtman et al. 1983; Wurtman and Wurtman 1979) . When animals are treated with anorectic doses of OF or FL, the subsequent reduction in calorie intake 0893-133X/93/$6.00 is also associated with a selective decrease in CHO con sumption; protein intake remains unchanged (Luo and Li 1991; Wurtman and Wurtman 1979) . In contrast, anorectic drugs that aff ect catecholamine-mediated neu rotransmission nonselectively decrease food intake (Moses and Wurtman 1984) . Obese humans who typi cally consume excessive amounts of CHO foods, par ticularly as snacks, reduce their CHO snack intake by approximately 40% in response to OF, but they do not significantly alter their protein consumption. Anorec tic doses of FL might be expected to similarly aff ect CHO intake because of this drug's similarity to OF in enhanc ing serotonin-mediated neurotransmission. However, recent studies indicate that anorectic doses of FL may affect catecholaminergic as well as serotoninergic neu rotransmission (Garattini et al. 1992 ; Grignaschi and Samanin in press) by inhibiting catecholamine reup take; moreover, rats treated with metergoline, a sero tonin-receptor antagonist, still respond to the anorec tic actions of FL but not OF (Garattini et al. 1992 ; Samanin et al. 1989) . If FL-mediated anorexia in humans also involves catecholaminergic mechanisms, then the drug'S influence on macronutrient intake may differ from that of OF. Little is known from clinical trials about specific changes in food intake following FL adminis tration. One study did investigate changes in appetite; the results indicated a lessening of appetite for CHO rich foods among individuals treated with FL but not with placebo (Ferguson and Feighner 1987) . However, that study was not designed to measure food intake directly and relied instead on subjective perception. The present study compares the effects of OF and FL treat ments on calorie, macronutrient intake, and weight loss among obese women. The subject population was re stricted to individuals who claimed to consume exces sive amounts of CHO-rich foods as snacks ("CHO cravers"), and whose pretreatment pattern of food in take confirmed this claim.
METHODS AND SUBJECTS

Subject Recruitment and Screening
Subjects were recruited through newspaper, radio, and mass transit advertisements directed at women who were 40 lbs to 60 lbs above ideal body weight, accord ing to the Metropolitan Life Insurance Height and Weight glucose, blood urea nitrogen, creatinine, total protein, albumin, calcium, phosphorous, total bilirubin, uric acid, cholesterol, triglyceride, sodium, potassium, chlo ride, total carbon dioxide, alkaline phosphate, lactic de hydrogenase, serum glutamic, oxaloacetic transami nase, serum glutamic-pyruvic transaminase).
Baseline Food Intake
One hundred and two subjects who were in good phys ical health (as determined by physical examination, blood chemistry, and electrocardiogram) and whose weight status met protocol criteria were asked to par ticipate in a 4-day outpatient measurement of their meal and snack intakes to identify those whose food intake reflected a consistent appetite for CHO-rich snack foods. Previous studies have shown that most obese subjects who claimed that their consumption of sweet and starchy snacks was associated with an inability to lose weight did in fact eat at least 30% of their total daily calories in the form of between-meal CHO-rich snacks (Wurtman et al. 1987) .
A two-phase approach was used to identify sub jects who would meet our criteria for CHO craving.
Prior to admission to the screening component of the study, interested subjects fIlled out a mailed question naire detailing their typical pattern of snack intake. This questionnaire asked them if they snacked daily and, if so, to indicate when during the day they snacked.
The subjects indicated, from a long list of protein-, CHO-, and fat-rich snacks as well as fruits and vegeta bles, which snacks they were most likely to eat. The questionnaire defmed "snacking" as eating between or after meals when subjects were not hungry. Subjects who indicated that they snacked daily on only CHO rich foods were then asked to participate in the base line measurement procedure.
The dietary department of the CRC provided the subjects with an assortment of isocaloric, low-fat, protein-rich, and CHO-rich foods in excess of what they might consume ( Table 1) . Meal foods contained an av erage of 32% Kcal from fat, and snack foods contained 26% Kcal from fat. The foods were packaged in preweighed, easily transported containers for con sumption away from home. The meal and snack food items provided by the study were relatively low in fat to make them compatible with the objectives of a weight-loss study. Subjects were told to eat spontane ously, not to restrict their food intake, and to consume on l y and the foods designated as snack foods for in-between meal snacks. A simple log book was provided in which the subject could check off the foods actually consumed against a printed list and could note the time of day when each food was eaten. The log book was designed such that the subjects could record whether they ate a particular food item as a meal or snack food, as well as the time of food consumption. Because it was possi ble that they would also consume foods other than those provided by the study, they were asked to note their consumption of those foods as well. All food containers and all uneaten food were returned to the dietician for weighing. The subjects were weighed prior to the food intake measurement and on the day of completion.
Activity Levels
Subjects kept a record of their physical activity for 4 days coincident with the period of baseline food intake mea surement. None of the subjects engaged in any formal exercise regime; physical activity was limited to that necessary for maintaining daily routines (i.e., walking from the car to work, climbing stairs in the home, meal preparation, carrying groceries, doing laundry, etc.) Most of the subjects' waking hours were spent seated.
Study Format
Subjects whose CHO intake as snacks met the protocol criteria were randomly assigned to a FL, OF, or placebo (PL) treatment group. The study was conducted in double-blind fashion; subjects received identical packets of three pills that provided a total of 60 mg FL, 30 mg OF, or PL. They were told to take one pill in the morning, one at noon, and one in the early evening; the noon pill in the OF packet was a placebo. The doses of FL and OF were those known to produce anorectic effects (Guy-Grand et al. 1989; Levine et al. 1987) . Sub jects were given a food plan that instructed them as to the number of servings and portion sizes they should consume to obtain their total daily nutrient require ments. The dietary information emphasized the impor tance of eating a variety of foods, and subjects were given exchange lists containing examples of nutrient dense, low-fat foods.
No additional information on weight loss was offered to the subjects. There was no discussion be tween the staff and subjects on exercise, behavioral modification, stressful events that might have affected weight loss, or nutritional information other than repeated admonitions to consume as little fat as possi ble. Because the subjects were entered individually into the study, no interaction between subjects was possi ble. The staff was uniformly considerate and kind to the subjects, many of whom reported after completion that weekly contact with the staff was an important posi tive component in their compliance with the study.
Measurements
Weight, vital signs, side effects, and assessments of mood and premenstrual symptomatology were ob tained on the day prior to the initiation of drug treat ment. The presence of depressive symptoms over the previous week was assessed using the interviewer administered Hamilton Depression Rating Scale (HDRS) (Hamilton 1967) , the self-administered ProfIle of Mood States (POMS) (McNair et al. 1971) , and the Center for Epidemiological Studies-Depression (CES D) (Radloff 1977) test. Subjects also ftlled out the Stand ford Sleepiness Scale (SSS) (Hoddes et al. 1973 ) and the Menstrual Symptomatology Questionnaire (MSQ) (Abraham 1981) . Baseline side effects were monitored by recording spontaneous descriptions of mood and physical status during the previous week. Following this, subjects were asked to report any illness or major life event that occurred during the previous week and to note the week of their menstrual cycle or, for meno pausal women, the week of hormone replacement ther apy. Blood was drawn for baseline drug levels and BPRO.
Subjects were treated for 12 weeks; they returned to the CRC weekly to receive their medications. At that time, their vital signs, side effects, and weight were evaluated and measured, and they ftlled out the POMS, CES-D, SSS, and MSQ forms. The research nurse reviewed the side-effect report with each subject prior to dispensing medication for the following week. The side-effect reports were also subsequently reviewed by the study physicians. Every fourth week, blood was drawn for measurement of drug levels and BPRO, and food intake was monitored over 4 days, using the methods described above for baseline food intake.
Two weeks following the end of the treatment period, subjects returned to the CRC for a posttreat ment assessment of drug levels and BPRO. At that time, they met with the research staff and were given infor mation on dietary intake and exercise. When subjects dropped out of the study, one of the research physi cians sent a full report of their medical and treatment status, along with their reasons for withdrawal, to the MIT COUHES.
Data Analysis
Weight, food intake, and test scores were analyzed using a two-factor repeated-measures analysis of vari ance with time as the repeated measure. Food intake was averaged for each 4-day measurement period. Post hoc pairwise comparisons among study group and time means were tested for signifIcance using the Newman-NEUROPSYCHOPHARMACOLOGY 1993-VOL. 9, NO.3 Kews test. Relationships between variables were tested for signifIcance using Pearson's product moment corre lation. Diff erences in distributions of dropouts and side effects among study groups were compared using the chi-square statistic. Data are expressed as means with standard errors of the mean used as the measure of dispersion. Statistical signifIcance was determined at p � .05.
RESULTS
Eighty-seven women qualifIed for entry into the study on the basis of data from the baseline food intake screen· ing. All of them met our criteria for CHO cravers, can· suming more than 40% of their total CHO intake as high-CHO snack foods and more than 30% of their to tal daily calories as such foods. (Protein intake from snacks accounted for slightly more than 20% of their total daily protein intake.) Fifteen subjects were elimi· nated during the screening period because they re stricted their calorie consumption during the food in take measurement period to under 1000 Kcal a day and admitted to the diet staff that they wanted to use the baseline period to initiate their weight loss regimen. Fat was a fIxed constituent of the meal and snack foods; subjects could not alter the fat contents of the foods by, for example, choosing to eat or avoid high-fat ingre dients such as butter or mayonnaise. Although the foods varied somewhat in the number of grams of fat they contained, the amount of fat the subject consumed was determined mainly by the number of servings of protein or CHO-rich foods that she chose to eat. How ever, the fat content of the foods was kept as low as possible because the subjects wowd be eating the same foods during the weight loss component of the study, and we did not want the foods used in the study to be incompatible with weight loss.
The three groups of subjects were similar in age, body mass index (BMI) ( Table 2 ) and in reporting a sedentary level of physical activity (Table 2) ; none showed evidence of depression on self-reported or interviewer-rated tests of mood at the time they entered the study (Table 2) .
Subjects were entered singly into each treatment group; 64 subjects completed the study: the PL group consisted of 25 of 29 initial subjects, OF 21 of 28 sub jects, and FL 18 of 30 subjects (Table 2) . Weight loss per week was calculated for all subjects (Le., for those who completed the study and for those who dropped out). No difference was found in the rate of weekly weight loss between completers and dropouts at the time the latter withdrew from the study; hence, the results given represent those of the total group. The weekly rates of weight loss were similar for the two drug treatment groups and signifIcantly greater than that of the PL treatment group (p = .039). The PL-treatedsub- jects lost 0.22 ± 0.06 kg per week, DF subjects lost 0.56 ± 0.08 kg per week, and FL subjects lost 0.58 ± 0.09 kg/per week (groups include both completers and noncompleters). The cumulative weight loss (of com pieters) at the end of the treatment period was also simi lar between drug-treated subjects and signifIcantly more than among those receiving PL (p < .05) (Fig. 1) . The PL-treated subjects lost 3.0 ± .74 kg, DF subjects lost 6.6 ± 0.96 kg, and FL subjects lost 7.1 ± 1.09 kg. The PL-treated subjects showed a small weight gain of ap proximately 0.14 ± 0.19 kg at the end of the 5th and 9th treatment weeks, and net losses at the end of all the other weeks. Because the amount of weight to be lost was similar but not identical among subjects, weight loss was also calculated as a percent of the amount of we ight that needed to be lost for each subject to attain ideal body weight. The PL-treated subjects lost 11.3% of this weight, DF subjects lost 27%, and FL subjects lost 26% (Fig. 2) .
Food Intake
All subjects consumed more than 40% of their total CHO intake from snacks during the baseline food in- • p < .05 diff ers from PL-treated group. take period. Protein intake from snacks accounted for slightly more than 20% of total daily protein intake. Daily calorie consumption was similar between all groups prior to the initiation of treatment (Table 3) . Sub jects consumed approximately 1250 calories from meals and 790 calories from snacks during the baseline period of food intake measurement. Their calorie intake dur ing the study may have underrepresented what they normally consumed inasmuch as the foods supplied by the CRC were probably lower in fat than those the sub jects would choose to consume at home or in a restau rant (Table 3) .
All treatments resulted in a decrease in calorie in take from meals and snacks; the reductions, however, were significantly greater for the drug-treated groups than for PL group. Decreased CHO intake from meals and snacks accounted for the greatest effect of the drugs on food intake (Table 3) . By the end of the third treat ment period, snack CHO intake by the PL-treated sub jects was decreased by 48% of baseline. The DF-treated subjects had decreased snack CHO intake by 75%, and FL-treated subjects decreased snack CHO intake by 60%. The decreases with DF and FL treatment were significantly greater than with PL (p < .05). Subjects were allowed to choose their meal and snack foods from among a variety of isocaloric, isofat, protein-and carbohydrate-rich items. The foods were supplied in excess of what the subjects nor mally consumed. Fat content was kept as low as possible, and its intake varied in relation to the consumption of the meal and snack foods. Food intake was measured over 4 days prior to the start of the drug treatment and over the 4, 8, and 12 weeks subjects were still receiving treatment.
CHO intake from meals was affected only by DF treatment (p < .025 vs. PL). Although those subjects receiving FL ate less CHO at mealtimes than PL, the difference was not signifIcant (Table 3) .
Protein intake from snacks represented the protein present in the designated "protein snacks" and the small quantities of protein present in "CHO snacks" ( Table   3 ). The proportion of total daily protein intake from snacks during the treatment periods was similar in all groups (PL, 11%; DF, 9%; and FL, 9%). Protein intake from meals during the baseline period was much higher than the recommended dietary allowance (Food and Nutrition Board 1989) among all three treatment groups.
Both drugs reduced meal protein intake signifIcantly more than PL (p < .05); however, none of the subjects in any group decreased protein intake below the recom mended amount.
Weight loss signifIcantly correlated with decreased snack CHO intake among the DF group (r = 0.485, P = .03) and with decreased mealtime protein intake among the FL group (r = 0.566, P = .014). Weight loss in the PL group was not correlated with any specifIc changes in macronutrient intake.
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Side Effects and Dropouts
The number of subjects who withdrew from the study due to side effects differed signifIcantly (p < .02) be tween the FL-treated subjects (seven) and the two ot her treatment groups (two, PL; one, DF) ( Table 4) . Lack of weight loss accounted for the withdrawal of two addi tional FL-treated subjects; all other subjects withdrew because of intercurrent illness or personal problems that interfered with their ability to comply with the study schedule. Almost all subjects, regardless of treatment, reported side effects during the study (PL, 24 of 29; DF, 23 of 28; FL, 27 of 30), and more side effects were reported during the frrst 4 weeks of the study than dur ing the subsequent 2 months ( Table 5 ).
The number of subjects reporting headaches was similar among all three treatment groups; anxiety was slightly more common among the PL-treated subjects ( Table 5 ). The types of side effects reported by subjects on the two drug treatments differed. Dry mouth (30%) and headache (18%) accounted for the majority of side effects reported by those on DF, whereas insomnia (22%) and fatigue (18%) were the most common side effects reported by those on FL ( Table 5 ). The FL-treated subjects reported signifIcantly more sleep disturbances and fatigue during the entire treatment period than the other two treatment groups (p < .005); the DF-treated subjects reported signifIcantly more complaints of dry mouth (p < .005).
Subjects who were menstruating were asked to complete a menstrual symptom checklist each week that rated changes in mood, appetite, sleep, and somatic symptoms. Among PL-treated subjects, self-reported appetite tended to increase premenstrually; both DF and FL-treated subjects showed signifIcantly less of an increase during the frrst treatment month (p < .018).
Depression was monitored through the use of the interviewer-administered HDRS, the self-repor ted POMS, and the CES-D scale prior to treatment ini tiation. The latter two tests were fLlled out weekly by the subjects throughout the 12 treatment weeks.
No signifIcant alterations from baseline scores were observed among any of the subjects, regardless of treatment.
DISCUSSION
Obese female subjects who consumed at least 40% of their total daily CHO intake from snack foods-and at least 30% of their total calories from such foods responded to treatment with DF or Fl by losing, on av erage, twice as much weight per week as PL-treated subjects. Moreover, both drugs were similar in help ing subjects to lose, in 12 weeks, slightly more than a quarter of the weight needed to attain ideal body weight for their height. The monthly food intake measurements indicated that both drugs similarly affected CHO intake from snacks, reducing it signmcantly more than PL treat ment. Only DF-treated subjects, however, demon strated a signilicant correlation between weight loss and decreased CHO snack intake; weight loss among FL treated correlated with decreased protein intake from meals.
Both drugs have well-established effects on weight loss: DF (30 mg) has been shown to cause more weight loss than PL in a large number of studies (Cairella et aI. 1991; Ditschuneit et al. 1991; Finer et a1. 1985 Finer et a1. , 1987 Guy-Grand et al. 1989; Noble 1990 ). Many short-term trials have shown the drug to reduce weight in obese patients over 3-to 6-month periods even among patients who were refractory to medical and nutritional super vision (Noble 1990 ). In a I-year placebo-controlled mul ticenter trial of 822 patients, weight loss during the frrst 6 months was greater in the DF-treated group than in the PL group (9.82 kg vs. 815 kg); this loss was main tained during the second 6 months by DF patients, but not by PL-treated subjects, whose weight increased (Guy-Grand et a1. 1989) . In a group of obese subjects undergoing smoking withdrawal, drug treatment was associated with weight loss; in comparison, PL-treated subjects gained weight (Spring et al. 1991 ). DexfenfluraSide Effects "Numb-headed, " "heavy-headed, " nausea, fatigue Tachycardia, dry mouth, nausea, headache, insomnia, accelerated transit time, light-headed, dizzy, restless "Too many side effects," fatigue, "numb-headed, " "heavy-headed" Headache, itching Headache, insomnia, fatigue & tremor, dizzy, "spacey, " nausea, upper GI distress, dry mouth Drowsiness, muscle aches, fatigue, insomnia, headache, diarrhea Insomnia, dry mouth, "feels different physicially," memory & concentration disturbances, yawning, anxiety, chills, "goosebumps, " vomiting, diarrhea, vivid dreams during which she hit her husband Abnormal values for plasma electrolytes Visual disturbance, fatigue, headache, palpitations, eructations, dizzy, anxiety, taste disturbance, drowsiness Elevated blood pressure, fatigue, tremor, insomnia, taste disturbance mine also inhibited weight gain among subjects with a history of Seasonal Affective Disorder (O'Rourke et al. 1989 ). Fluoxetine administered to obese subjects in daily doses ranging from 40 mg to 80 mg (Ferguson and Feighner 1987; Levine et al. 1987; Wise 1992 ) was signilicantly more effective than PL in producing weight loss over 8-week periods. It has been reported (Pijl et al. 1991 ) that obese females treated for 6 weeks with 60 mg/ day of FL lost weight, whereas PL-treated sub jects gained weight. Scientists (Orzack et al. 1990 ) have observed that treatment for 2 months with 20 mg/day to 80 mg/day of FL also caused weight loss among depressed obese patients, although treatment for 4 months caused weight gain among patients whose starting weight was normal for their height. We did not see any evidence of weight gain with FL treatment, al though two subjects dropped out of the study due to lack of weight loss after 3 to 4 weeks of treatment. In a study lasting 52 weeks (Darga et al. 1991) , it was found that FL (60 mg/day) treatment caused a maximum weight loss at week 29, followed by substantial weight gain, such that no diff erences were seen in total weight loss between drug and placebo treatment by the end of the study. Weight gain over a 4-to 24-month period ranged from 10 to 30 pounds. These data include symptoms reported by all subjects, both com pieters and dropouts. Side effects were assessed weekly by spon taneous report and recorded by a trained investigator.
Direct measurements of food intake revealed a signifIcantly greater decrease in consumption of CHO rich foods among drug-treated than among PL-treated subjects. These £mdings confrrm earlier animal and clin ical studies in which treatment with drugs that increase intrasynaptic serotonin was shown to suppress CHO NEUROPSYCHOPHARMACOLOGY 1993-VOL. 9, NO.3 intake. That serotonin participates in the regulation of CHO intake (Blundell 1992; Leibowitz and Shor-Posner 1987) is based on the observation that increased sero tonin synthesis following consumption of CHO-rich meals (Blum et al. 1992; Fernstrom and Wurtman 1973; Lyons and Truswell 1988) leads to a subsequent de crease in CHO intake (Wurtman et al. 1983) . A similar decrease in CHO, but not protein, intake is seen after intrasynaptic serotonin levels are increased by treat ment with anorectic drugs (Cangiano et al. 1992; Hill and Blundell 1986; Luo and Li 1991; Wurtman and Wurtman 1979) . Administration of FL or DF to animals given access to isoenergetic diets diff ering in protein and CHO contents decreased the consumption of onl y the high CHO diet (Cangiano et al. 1992; Hill and Blun dell 1986; Luo and Li 1991; Wurtman and Wurtman 1979) . Similarly, DF administration to CHO cravers (Wurtman et al. 1985; Wurtman et al. 1987) , women with Late Luteal Dysphoric Syndrome (Brzezinski et al. 1990) , and individuals going through smoking with drawal selectively suppressed CHO but not protein in take. Although measured subjectively, the decreased appetite for CHO-rich foods previously reported by sub jects treated with FL provides additional evidence of the participation of serotonin in controlling CHO in take (Ferguson and Feighner 1987) . The results of the present study provide additional evidence that both DF and FL exert their anorectic effect primarily through serotonin-mediated decreases in CHO intake and confrrm through direct measurement of food intake the observation of Ferguson and Feighner of a subjective decrease in appetite for CHO-rich foods (Ferguson and Feighner 1987) .
There is some disagreement, however, as to whether treatments that enhance serotonin availabil ity affect the intake of protein and fat as well as of CHO. It has been found (Cangiano et al. 1992 ) that obese in dividuals treated with 5-hydroxytryptophan signifI cantly reduced both fat and CHO consumption. A de cline in protein intake was also reported in this study, but this was not signifIcant. In the present study, as in those conducted earlier in our laboratory, DF treat ment did decrease protein intake but the magnitude of this change was considerably smaller than the reduc tion in CHO consumption (Wurtman et al. 1985) . The effect of altering serotonin availability through drug treatment on macronutrient intake may be affected by the weight of the subjects and the duration of treatment. In 1992, scientists treated nonobese males with DF and measured food intake several hours after the drug was administered. They found that DF had no effect on pro tein, fat, or sweet CHO intake and reduced CHO con sumption only from nonsweet CHO foods such as bread (Goodall et al. 1992) .
Finally, the effects of agents such as DF on macro nutrient intake in animals may be dependent on the particular stage of the diurnal cycle during which feed ing is measured. Weiss et al. (1990) found that rats treated with OF selectively reduced their consumption of CHO only at the onset of the nocturnal period (i.e., when the animals eat most of their food). No effect on macronutrient intake was observed in the middle and late hours of the dark phase (Weiss et al. 1990 ). The availability of new selective serotonin reuptake inhibi tors such as sertraline and paroxetine may help resolve the issues involving macronutrient specifIcity.
Protein intake from meals was decreased more by drug than by PL treatment; none of the treatments, however, decreased protein intake below the recom mended dietary allowance (Food and Nutrition Board 1989). The effects of OF and FL on the consumption of high-fat foods such as butter, cream, salad dressings, cheese, and bacon were not assessed in this study.
However, because most of the protein-and CHO-rich test foods used in the study also contained fat, the reduction of food intake during the treatment period inevitably led to a decrease in fat intake and in the in take of fat calories.
Measurement of the correlation between weight loss and macronutrient intake, revealed differences be tween the two drugs; decreased CHO intake from snacks was correlated with weight loss among the OF treated subjects, whereas protein intake from meals was correlated with weight loss among FL-treated subjects.
It is difficult to interpret these results because FL de creased CHO snack intake to the same degree as OF.
More information would be needed concerning food intake in the subjects' usual surroundings to verify these correlations.
The two drugs differed in their side-effect proflies.
The most common side effects seen among OF-treated subjects were dry mouth, fatigue, and diarrhea. The FL-treated subjects reported insomnia and fatigue as the most persistent side effects. Most subjects in all three groups reported side effects, especially during the frrst month of treatment; those receiving FL, however, were the most likely to drop out of the study in response to their symptoms. We examined the weight loss, mood proflie, initial weight, and health history of the seven FL-group dropout subjects and found no pretreatment diff erences between them and the subjects who re mained in the study. Only one OF subject left the study for health reasons (increased blood pressure); two on bound-eating after its discontinuation as reported in other studies.
The foods that we used for measurement of calorie and macronutrient intake were relatively low in fat, with most of the CHO-rich snacks containing 2 g or 3 g of fat and the protein snacks containing 5 g or less of fat ( Table 1) . This may account for the somewhat low calorie intake of the subjects at baseline; presumably their calorie and fat consumption would be higher from foods they selected for themselves. We found, how ever, that our subjects responded positively to the avail ability of very low CHO foods, especially snack foods, and informed us that they were unaware until enter ing the study that it was possible to snack without con suming large amounts of fat. It may thus be that the PL-treated subjects responded as well as they did be cause they learned from our study that they could satisfy their CHO cravings without consuming foods that were also high in fat.
